Target intelligence / Profile preview

MicroRNA 6075 (MIR6075)

Target
MIR6075
Molecular classification
MicroRNA, Non-coding RNA
01

Overview

MicroRNA 6075 is a small non-coding RNA molecule that belongs to the microRNA (miRNA) class, typically 21–23 nucleotides in length[5]. Like other miRNAs, it is presumed to regulate gene expression post-transcriptionally by binding to complementary sequences in the 3' untranslated regions of messenger RNAs, resulting in translational suppression or degradation of the target mRNA[5][6]. The specific physiological role and validated gene targets of miR-6075 in humans have yet to be elucidated. However, recent studies have highlighted its significance in oncology: elevated serum levels of miR-6075, particularly when paired with miR-1268b, serve as sensitive and specific biomarkers for early detection of resectable lung cancer[2][3]. Additionally, miR-6075 has been associated with the detection of pancreatic and biliary tract cancers[2][3]. Currently, microRNA 6075 is mainly utilized as a diagnostic biomarker rather than a direct therapeutic target. Its specific functions, validated molecular interactions, and mechanistic contributions to cancer biology remain undetermined. As such, MIR6075 does not fit established categories like "receptor," "enzyme," or "transporter" and should be considered *incorrect* as a classic therapeutic target, given the absence of sufficient functional data and clinical evidence[2][3]. There is a lack of information on drugs directly modulating MIR6075 and its mechanism as a drug target. Whether miR-6075 might be modulated by future oligonucleotide therapies (e.g., antisense, miRNA mimics or inhibitors) remains unknown. There are no notable safety concerns, adverse effect profiles, or patient selection algorithms specific to miR-6075 in clinical use. Aliases given reflect typical miRNA naming conventions for human microRNAs. In summary, MicroRNA 6075 (MIR6075) is a non-coding RNA molecule with emerging relevance as a cancer biomarker, but it is not currently a well-characterized therapeutic target; information on its biological roles and mechanisms is incomplete[2][3][5].

Other names
hsa-mir-6075microRNA mir-6075MIR6075
02

Biological functions

Post-transcriptional gene regulation (putative)RNA silencing (general for microRNAs)
03

Disease associations

Cancer (biomarker in lung, pancreatic, and biliary tract cancers)
04

Biomarkers

Serum miR-6075 is a biomarker for resectable lung cancer and for pancreatic/biliary tract cancers, particularly in combination with miR-1268b

Beyond the preview

Go deeper on MicroRNA 6075 (MIR6075).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 6075 (MIR6075).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call